214 related articles for article (PubMed ID: 26773746)
1. A Jonah-like chymotrypsin from the therapeutic maggot Lucilia sericata plays a role in wound debridement and coagulation.
Pöppel AK; Kahl M; Baumann A; Wiesner J; Gökçen A; Beckert A; Preissner KT; Vilcinskas A; Franta Z
Insect Biochem Mol Biol; 2016 Mar; 70():138-47. PubMed ID: 26773746
[TBL] [Abstract][Full Text] [Related]
2. Maggot excretion products from the blowfly Lucilia sericata contain contact phase/intrinsic pathway-like proteases with procoagulant functions.
Kahl M; Gökçen A; Fischer S; Bäumer M; Wiesner J; Lochnit G; Wygrecka M; Vilcinskas A; Preissner KT
Thromb Haemost; 2015 Aug; 114(2):277-88. PubMed ID: 25948398
[TBL] [Abstract][Full Text] [Related]
3. Towards next generation maggot debridement therapy: transgenic Lucilia sericata larvae that produce and secrete a human growth factor.
Linger RJ; Belikoff EJ; Yan Y; Li F; Wantuch HA; Fitzsimons HL; Scott MJ
BMC Biotechnol; 2016 Mar; 16():30. PubMed ID: 27006073
[TBL] [Abstract][Full Text] [Related]
4. Degradation of extracellular matrix components by defined proteinases from the greenbottle larva Lucilia sericata used for the clinical debridement of non-healing wounds.
Chambers L; Woodrow S; Brown AP; Harris PD; Phillips D; Hall M; Church JC; Pritchard DI
Br J Dermatol; 2003 Jan; 148(1):14-23. PubMed ID: 12534589
[TBL] [Abstract][Full Text] [Related]
5. [Lucifensin, Chymotrypsin Proteins and Molecular Characterization of Lucilia sericata].
Erdoğan E; Karaca S
Mikrobiyol Bul; 2021 Jan; 55(1):81-90. PubMed ID: 33590983
[TBL] [Abstract][Full Text] [Related]
6. Maggot chymotrypsin I from Lucilia sericata is resistant to endogenous wound protease inhibitors.
Telford G; Brown AP; Kind A; English JS; Pritchard DI
Br J Dermatol; 2011 Jan; 164(1):192-6. PubMed ID: 21175562
[TBL] [Abstract][Full Text] [Related]
7. Urate Oxidase produced by Lucilia sericata medical maggots is localized in Malpighian tubes and facilitates allantoin production.
Baumann A; Skaljac M; Lehmann R; Vilcinskas A; Franta Z
Insect Biochem Mol Biol; 2017 Apr; 83():44-53. PubMed ID: 28235562
[TBL] [Abstract][Full Text] [Related]
8. Degradation of eschar from venous leg ulcers using a recombinant chymotrypsin from Lucilia sericata.
Telford G; Brown AP; Seabra RA; Horobin AJ; Rich A; English JS; Pritchard DI
Br J Dermatol; 2010 Sep; 163(3):523-31. PubMed ID: 20491762
[TBL] [Abstract][Full Text] [Related]
9. Recombinant Lucilia sericata chymotrypsin in a topical hydrogel formulation degrades human wound eschar ex vivo.
Britland S; Smith A; Finter W; Eagland D; Vowden K; Vowden P; Telford G; Brown A; Pritchard D
Biotechnol Prog; 2011; 27(3):870-4. PubMed ID: 21509949
[TBL] [Abstract][Full Text] [Related]
10. Wound debridement potential of glycosidases of the wound-healing maggot, Lucilia sericata.
Telford G; Brown AP; Rich A; English JS; Pritchard DI
Med Vet Entomol; 2012 Sep; 26(3):291-9. PubMed ID: 22620282
[TBL] [Abstract][Full Text] [Related]
11. Midgut lysozymes of Lucilia sericata - new antimicrobials involved in maggot debridement therapy.
Valachova I; Takac P; Majtan J
Insect Mol Biol; 2014 Dec; 23(6):779-87. PubMed ID: 25098233
[TBL] [Abstract][Full Text] [Related]
12. The effect of Lucilia sericata larval excretion/secretion (ES) products on cellular responses in wound healing.
Gazi U; Taylan-Ozkan A; Mumcuoglu KY
Med Vet Entomol; 2021 Sep; 35(3):257-266. PubMed ID: 33314340
[TBL] [Abstract][Full Text] [Related]
13. Detection and partial characterization of antifungal bioactivity from the secretions of the medicinal maggot, Lucilia sericata.
Evans R; Dudley E; Nigam Y
Wound Repair Regen; 2015; 23(3):361-8. PubMed ID: 25847128
[TBL] [Abstract][Full Text] [Related]
14. A molecular approach to maggot debridement therapy with Lucilia sericata and its excretions/secretions in wound healing.
Tombulturk FK; Kanigur-Sultuybek G
Wound Repair Regen; 2021 Nov; 29(6):1051-1061. PubMed ID: 34343386
[TBL] [Abstract][Full Text] [Related]
15. Effects of Lucilia sericata on wound healing in streptozotocin-induced diabetic rats and analysis of its secretome at the proteome level.
Tombulturk FK; Kasap M; Tuncdemir M; Polat E; Sirekbasan S; Kanli A; Kanigur-Sultuybek G
Hum Exp Toxicol; 2018 May; 37(5):508-520. PubMed ID: 28621210
[TBL] [Abstract][Full Text] [Related]
16. Maggot debridement therapy and complementary wound care: a case series from Nigeria.
Yusuf MA; Ibrahim BM; Oyebanji AA; Abubakar F; Ibrahim M; Ibrahim Jalo R; Aminu A; Akbarzadeh K; Azam M; Sheshe AA; Ganiyu OO; Abubakar MK; Salisu WJ; Kordshouli RS; Adamu AY; Takalmawa H; Daneji I; Aliyu M; Ibrahim MG; Kabuga AI; Abdullahi AS; Abbas MA
J Wound Care; 2022 Nov; 31(11):996-1005. PubMed ID: 36367805
[TBL] [Abstract][Full Text] [Related]
17. Maggot debridement therapy for an electrical burn injury with instructions for the use of Lucilia sericata larvae.
Nasoori A; Hoomand R
J Wound Care; 2017 Dec; 26(12):734-741. PubMed ID: 29244970
[TBL] [Abstract][Full Text] [Related]
18. Maggot debridement therapy with Lucilia cuprina: a comparison with conventional debridement in diabetic foot ulcers.
Paul AG; Ahmad NW; Lee HL; Ariff AM; Saranum M; Naicker AS; Osman Z
Int Wound J; 2009 Feb; 6(1):39-46. PubMed ID: 19291114
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Chronic Wound Debridement with the Use of Larvae of
Bazaliński D; Kózka M; Karnas M; Więch P
J Clin Med; 2019 Nov; 8(11):. PubMed ID: 31684038
[TBL] [Abstract][Full Text] [Related]
20. [Maggot therapy with Lucilia sericata for debridement of chronic wounds].
Cartier E; Combemale P
Ann Dermatol Venereol; 2008 Oct; 135(10):685-8. PubMed ID: 18929922
[No Abstract] [Full Text] [Related]
[Next] [New Search]
